MRTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MRTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-07), Mirati Therapeutics's current share price is $58.70. Mirati Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was $0.76. Mirati Therapeutics's Cyclically Adjusted PS Ratio for today is 77.24.
The historical rank and industry rank for Mirati Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Mirati Therapeutics's highest Cyclically Adjusted PS Ratio was 231.20. The lowest was 2.46. And the median was 62.38.
MRTX's Cyclically Adjusted PS Ratio is not rankedThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Mirati Therapeutics's adjusted revenue per share data for the three months ended in Sep. 2023 was $0.252. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.76 for the trailing ten years ended in Sep. 2023.
The historical data trend for Mirati Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirati Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 91.33 | 63.11 | 51.96 | 49.09 | 57.52 |
For the Biotechnology subindustry, Mirati Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Mirati Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Mirati Therapeutics's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Mirati Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 58.70 | / | 0.76 | |
= | 77.24 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mirati Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 is calculated as:
For example, Mirati Therapeutics's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Sep. 2023 (Change) | * | Current CPI (Sep. 2023) |
= | 0.252 | / | 129.8595 | * | 129.8595 | |
= | 0.252 |
Current CPI (Sep. 2023) = 129.8595.
Mirati Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201312 | 0.000 | 98.326 | 0.000 |
201403 | 0.000 | 99.695 | 0.000 |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | 0.000 | 99.070 | 0.000 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.000 | 101.688 | 0.000 |
201609 | 0.000 | 101.861 | 0.000 |
201612 | 0.000 | 101.863 | 0.000 |
201703 | 0.000 | 102.862 | 0.000 |
201706 | 0.000 | 103.349 | 0.000 |
201709 | 0.000 | 104.136 | 0.000 |
201712 | 0.000 | 104.011 | 0.000 |
201803 | 0.328 | 105.290 | 0.405 |
201806 | 0.000 | 106.317 | 0.000 |
201809 | 0.000 | 106.507 | 0.000 |
201812 | 0.106 | 105.998 | 0.130 |
201903 | 0.036 | 107.251 | 0.044 |
201906 | 0.016 | 108.070 | 0.019 |
201909 | 0.025 | 108.329 | 0.030 |
201912 | 0.013 | 108.420 | 0.016 |
202003 | 0.006 | 108.902 | 0.007 |
202006 | 0.000 | 108.767 | 0.000 |
202009 | 0.256 | 109.815 | 0.303 |
202012 | 0.035 | 109.897 | 0.041 |
202103 | 0.000 | 111.754 | 0.000 |
202106 | 0.000 | 114.631 | 0.000 |
202109 | 1.390 | 115.734 | 1.560 |
202112 | 0.006 | 117.630 | 0.007 |
202203 | 0.013 | 121.301 | 0.014 |
202206 | 0.097 | 125.017 | 0.101 |
202209 | 0.097 | 125.227 | 0.101 |
202212 | 0.016 | 125.222 | 0.017 |
202303 | 0.124 | 127.348 | 0.126 |
202306 | 0.235 | 128.729 | 0.237 |
202309 | 0.252 | 129.860 | 0.252 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Mirati Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Jamie Christensen | officer: Sr. Vice President, Chief Scie | C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121 |
Benjamin Hickey | officer: EVP, Chief Commercial Officer | C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121 |
Aaron Ondrey | officer: Interim CFO | 3545 CRAY COURT, SAN DIEGO CA 92121 |
Boxer Capital, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Christopher Fuglesang | other: See remarks | 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130 |
Shehan Bharatha Dissanayake | other: See remarks | 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130 |
Aaron I. Davis | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Mva Investors, Llc | other: See remarks | 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130 |
Boxer Asset Management Inc. | other: See remarks | CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000 |
Joseph Lewis | other: See remarks | PO BOX N7776, LYFORD BAHAMAS |
Faheem Hasnain | director | 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
John B Moriarty | officer: Chief Legal Officer | ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Carol Giltner Gallagher | director | C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Laurie Stelzer | officer: CFO | 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Julie M Cherrington | director | 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121 |
From GuruFocus
By PRNewswire • 10-10-2023
By PRNewswire • 09-10-2023
By PRNewswire • 11-14-2023
By Business Wire • 10-09-2023
By Business Wire • 10-09-2023
By PRNewswire • 11-03-2023
By GuruFocus Research • 01-12-2024
By PRNewswire • 08-23-2023
By PRNewswire • 09-05-2023
By Marketwired • 10-11-2023